01 Growing Shift Toward Targeted and Steroid-Sparing Therapies The uveitis treatment market is shifting from prolonged corticosteroid use toward targeted biologics, oral immune-modulating drugs, and locally delivered therapies. This change is driven by the risks of long-term steroid treatment, including cataracts, glaucoma, diabetes, and osteoporosis. Drug developers are targeting specific inflammatory pathways such as IL-6, VEGF, JAK1, and TYK2 to control inflammation while reducing systemic exposure. Sustained-release injections and bispecific medicines are also gaining attention because they may extend treatment intervals, manage macular edema, and improve adherence among patients requiring long-term care. For instance, in Oct 2025, Roche presented Phase III findings from the MEERKAT and SANDCAT trials evaluating vamikibart for uveitic macular edema.
01 Rising Need for Effective Control of Sight-Threatening Inflammation Growing diagnosis of autoimmune and infectious eye inflammation is increasing demand for corticosteroids, immunosuppressants, biologics, and antimicrobial treatments. Uveitis can recur and may cause macular edema, retinal damage, glaucoma, cataracts, or permanent vision loss when treatment is delayed. Demand is also supported by better retinal imaging, wider referral to ophthalmologists, and improved recognition of uveitis associated with juvenile idiopathic arthritis and other systemic diseases. Patients with recurring non-infectious uveitis often require long-term therapy, creating continued demand for medicines that maintain inflammation control while limiting cumulative steroid exposure.
01 Safety Risks and High Cost of Long-Term Treatment The market is restrained by the side effects, monitoring requirements, and expense associated with prolonged uveitis therapy. Corticosteroids can control inflammation quickly, but extended exposure may cause cataracts, glaucoma, osteoporosis, weight gain, and diabetes. Immunosuppressants and biologics can reduce steroid dependence, although they may increase infection risks and require laboratory testing. Advanced injections and biologic medicines can also be costly or difficult to obtain in countries with limited reimbursement. Because uveitis has infectious, autoimmune, and unexplained causes, an unsuitable immune-suppressing treatment may worsen an undiagnosed infection and delay recovery.
01 Development of Targeted Oral and Local Ocular Therapies Strong opportunities exist for medicines that control uveitis without prolonged systemic steroid exposure. Oral targeted therapies may offer convenient treatment for non-infectious disease, while intravitreal biologics can deliver medicine directly to the eye and limit effects elsewhere in the body. Companies can also address uveitic macular edema, a major cause of vision loss, through therapies targeting inflammation and vascular leakage together. Expanding biosimilar availability, teleophthalmology, retinal imaging, and specialist services could further improve diagnosis and access in underserved countries. Products offering longer durability, fewer injections, and simpler monitoring may achieve stronger adoption.
01 Complex Diagnosis and Highly Variable Treatment Response Uveitis is not one disease; it includes multiple inflammatory conditions affecting different parts of the eye. Its causes may be autoimmune, bacterial, viral, fungal, parasitic, drug-related, or unknown. This diversity makes diagnosis, trial recruitment, treatment selection, and outcome measurement difficult. Symptoms can resemble other eye disorders, while immune suppression given before excluding infection may create serious complications. Disease recurrence also varies between patients, requiring repeated examinations and treatment adjustments. Limited access to uveitis specialists and advanced retinal imaging remains a major challenge, particularly in lower-income healthcare systems.
June 2026 AbbVie expanded its immunology portfolio with continued global adoption initiatives for Rinvoq® (upadacitinib) and research programs targeting immune-mediated inflammatory diseases, supporting broader innovation in autoimmune eye disorder treatment areas.
May 2026 Santen Pharmaceutical expanded its ophthalmology pipeline through continued development and commercialization of therapies targeting inflammatory eye diseases, strengthening its focus on uveitis and related ocular conditions.
March 2026 Bausch + Lomb expanded its ophthalmic pharmaceutical portfolio with continued investments in prescription eye-care solutions, including treatments addressing inflammatory and retinal eye disorders.
January 2026 EyePoint Pharmaceuticals advanced its sustained-release drug delivery platform research, supporting potential future applications in chronic ocular inflammatory conditions requiring long-term therapeutic administration.